Inhibikase Therapeutics Inc (NASDAQ:IKT) — Market Cap & Net Worth
Market Cap & Net Worth: Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics Inc (NASDAQ:IKT) has a market capitalization of $119.23 Million ($119.23 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18621 globally and #4330 in its home market, demonstrating a -4.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhibikase Therapeutics Inc's stock price $2.30 by its total outstanding shares 74516635 (74.52 Million). Also see how large is Inhibikase Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Inhibikase Therapeutics Inc Market Cap History: 2020 to 2026
Inhibikase Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $3.08 Billion to $171.39 Million (-43.26% CAGR). Also see IKT cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Inhibikase Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #524 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1806 of 3165 |
Weight: Inhibikase Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inhibikase Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhibikase Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Inhibikase Therapeutics Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
363.29x
Inhibikase Therapeutics Inc's market cap is 363.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.08 Billion | $698.47K | -$2.88 Million | 4416.79x | N/A |
| 2021 | $657.24 Million | $3.10 Million | -$14.81 Million | 211.97x | N/A |
| 2022 | $223.55 Million | $123.44K | -$17.91 Million | 1811.00x | N/A |
| 2023 | $94.64 Million | $260.50K | -$19.03 Million | 363.29x | N/A |
Competitor Companies of IKT by Market Capitalization
Companies near Inhibikase Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review IKT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Inhibikase Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Inhibikase Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Inhibikase Therapeutics Inc's market cap moved from $3.08 Billion to $ 171.39 Million, with a yearly change of -43.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $171.39 Million | +12.20% |
| 2025 | $152.76 Million | -36.92% |
| 2024 | $242.18 Million | +155.91% |
| 2023 | $94.64 Million | -57.67% |
| 2022 | $223.55 Million | -65.99% |
| 2021 | $657.24 Million | -78.70% |
| 2020 | $3.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Inhibikase Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $119.23 Million USD |
| MoneyControl | $119.23 Million USD |
| MarketWatch | $119.23 Million USD |
| marketcap.company | $119.23 Million USD |
| Reuters | $119.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more